Seoulin Bioscience Co.Ltd (038070) — Capital Reinvestment Ratio

Latest as of December 2025: 0.02x

Seoulin Bioscience Co.Ltd (038070) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow (₩631.76 Million) in capital expenditures (₩10.90 Million). See debt-free asset ratio of Seoulin Bioscience Co.Ltd to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

₩631.76 Million
KRW

Capital Expenditures

₩10.90 Million
KRW

Data as of

Dec 2025
Most recent filing

Seoulin Bioscience Co.Ltd Capital Reinvestment Ratio (2013–2025)

This chart tracks Seoulin Bioscience Co.Ltd's Capital Reinvestment Ratio across 11 annual periods. Check cash flow reinvestment rate of Seoulin Bioscience Co.Ltd to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Seoulin Bioscience Co.Ltd (2013–2025)

Year-by-year Capital Reinvestment Ratio for Seoulin Bioscience Co.Ltd from 2013 to 2025. For live market cap and broader valuation context, see 038070 market cap overview.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2025 0.11x ₩4.76 Billion ₩507.47 Million ▼ -89.8%
2023 1.05x ₩930.57 Million ₩974.21 Million ▲ +459.1%
2021 0.19x ₩8.92 Billion ₩1.67 Billion ▲ +71.9%
2020 0.11x ₩3.68 Billion ₩401.34 Million ▲ +196.1%
2019 0.04x ₩7.32 Billion ₩269.29 Million ▼ -62.4%
2018 0.10x ₩4.17 Billion ₩408.02 Million ▼ -98.5%
2017 6.71x ₩1.30 Billion ₩8.73 Billion ▲ +156.1%
2016 2.62x ₩2.76 Billion ₩7.21 Billion ▲ +188.0%
2015 0.91x ₩4.12 Billion ₩3.74 Billion ▲ +227.0%
2014 0.28x ₩2.74 Billion ₩761.57 Million ▲ +2367.3%
2013 0.01x ₩4.94 Billion ₩55.65 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow